Recurrent preterm birth 157

Recurrent preterm birth 157

213. Kim YM, Bujold E, Chaiworapongsa T, et al: Failure of physiologic 237. Brancazio LR, Murtha AP, Heine RP: Prevention of recurrent preterm transformation of the spiral arteries in patients with preterm labor and

delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med intact membranes. Am J Obstet Gynecol 189:1063-1069, 2003

349:1087-1088, 2003

214. Lyall F: Mechanisms regulating cytotrophoblast invasion in normal 238. Doggrell SA: Recurrent hope for the treatment of preterm delivery. pregnancy and pre-eclampsia. Aust N Z J Obstet Gynaecol 46:266-

Expert Opin Pharmacother 4:2363-66, 2003 273, 2006

239. Einstein FH, Bracero LA: Progesterone and preterm birth. Am J Obstet 215. Robertson WB, Brosens I, Dixon HG: The pathological response of the

Gynecol 190:1798-1799, 2004

vessels of the placental bed to hypertensive pregnancy. J Pathol Bac- 240. Keirse MJ: Progesterone and preterm: seventy years of “deja vu” or teriol 93:581-592, 1967

“still to be seen”? Birth 31:230-235, 2004 216. Gerretsen G, Huisjes HJ, Elema JD: Morphological changes of the

241. Di Renzo GC, Mattei A, Gojnic M, et al: Progesterone and pregnancy. spiral arteries in the placental bed in relation to pre-eclampsia and

Curr Opin Obstet Gynecol 17:598-600, 2005 fetal growth retardation. Br J Obstet Gynaecol 88:876-881, 1981

242. Ness A, Dias T, Damus K, et al: Impact of the recent randomized trials 217. Sheppard BL, Bonnar J: Ultrastructural abnormalities of placental villi

on the use of progesterone to prevent preterm birth: a 2005 follow-up in placentae from pregnancies complicated by intrauterine fetal

survey. Am J Obstet Gynecol 195:1174-1179, 2006 growth retardation: their relationship to decidual spiral arterial le-

243. da Fonseca EB, Bittar RE, Carvalho MH, et al: Prophylactic adminis- sions. Placenta 1:145-156, 1980

tration of progesterone by vaginal suppository to reduce the incidence 218. Norwitz ER: Defective implantation and placentation: laying the blue-

of spontaneous preterm birth in women at increased risk: a random- print for pregnancy complications. Reprod Biomed Online 13:591-

ized placebo-controlled double-blind study. Am J Obstet Gynecol 599, 2006

188:419-424, 2003

219. Burton GJ, Jauniaux E: Placental oxidative stress: from miscarriage to 244. Meis PJ, Klebanoff M, Thom E, et al: Prevention of recurrent preterm preeclampsia. J Soc Gynecol Investig 11:342-352, 2004

delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 220. Redman CW: Immunological aspects of pre-eclampsia. Baillieres Clin

348:2379-2385, 2003

Obstet Gynaecol 6:601-615, 1992 245. Spong CY, Meis PJ, Thom EA, et al: Progesterone for prevention of 221. Chwalisz K: The use of progesterone antagonists for cervical ripening

recurrent preterm birth: impact of gestational age at previous delivery. and as an adjunct to labour and delivery. Hum Reprod 9:131-161,

Am J Obstet Gynecol 193:1127-1131, 2005 1994 (suppl 1)

246. Caritis S, Rouse DJ: A randomized controlled trial of 17-hydroxipro- 222. Gorodeski IG, Geier A, Lunenfeld B, et al: Progesterone (P) receptor

gesterone caproate (17-OHPC) for the prevention of preterm birth in dynamics in estrogen primed normal human cervix following P injec-

twins. Am J Obstet Gynecol 6:S2, 2007 tion. Fertil Steril 47:108-113, 1987

223. Stjernholm Y, Sahlin L, Akerberg S, et al: Cervical ripening in humans: 247. Dodd JM, Flenady V, Cincotta R, et al: Prenatal administration of potential roles of estrogen, progesterone, and insulin-like growth fac-

progesterone for preventing preterm birth. Cochrane Database Syst tor-I. Am J Obstet Gynecol 174:1065-1071, 1996

Rev CD004947, 2006 248. Dodd JM, Crowther CA, Cincotta R, et al: Progesterone supplemen-

224. Johnson JW, Austin KL, Jones GS, et al: Efficacy of 17alpha-hy- tation for preventing preterm birth: a systematic review and meta- droxyprogesterone caproate in the prevention of premature labor.

N Engl J Med 293:675-680, 1975 analysis. Acta Obstet Gynecol Scand 84:526-533, 2005 225. Hill LM, Johnson CE, Lee RA: Prophylactic use of hydroxyprogester-

249. Sanchez-Ramos L, Kaunitz AM, Delke I: Progestational agents to pre- one caproate in abdominal surgery during pregnancy. A retrospective

vent preterm birth: a meta-analysis of randomized controlled trials. evaluation. Obstet Gynecol 46:287-290, 1975

Obstet Gynecol 105:273-279, 2005

226. Breart G, Lanfranchi M, Chavigny C, et al: A comparative study of the 250. Odibo AO, Stamilio DM, Macones GA, et al: 17alpha-hydroxyproges- efficiency of hydroxyprogesterone caproate and of chlormadinone

terone caproate for the prevention of preterm delivery: a cost-effec- acetate in the prevention of premature labor. Int J Gynaecol Obstet

tiveness analysis. Obstet Gynecol 108:492-499, 2006 16:381-384, 1979

251. Advisory Committee for Reproductive Health Drugs Meeting. the safety 227. Johnson JW, Lee PA, Zachary AS, et al: High-risk prematurity: pro-

and efficacy of New Drug Application (NDA 21-945), proposed trade gestin treatment and steroid studies. Obstet Gynecol 54:412-418,

name Gestiva, 17 alpha-hydroxyprogesterone caproate injection, 250 1979

mg/mL, Adeza Biomedical, for the proposed indication prevention of 228. Hartikainen-Sorri AL, Kauppila A, Tuimala R: Inefficacy of 17 alpha-

preterm delivery in women with a history of a prior preterm delivery. hydroxyprogesterone caproate in the prevention of prematurity in

Available at: http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006- twin pregnancy. Obstet Gynecol 56:692-695, 1980

4227M1.pdf . Last accessed August 29, 2006 229. Hauth JC, LC III, Brekken AL, et al: The effect of 17 alpha-hy-

252. Christian MS, Brent RL, Calda P: Embryo–fetal toxicity signals for droxyprogesterone caproate on pregnancy outcome in an active-duty

17a-hydroxyprogesterone caproate in high-risk pregnancies: A review military population. Am J Obstet Gynecol 146:187-190, 1983

of the non-clinical literature for embryo–fetal toxicity with progestins. 230. Yemini M, Borenstein R, Dreazen E, et al: Prevention of premature

J Matern Fetal Neonatal Med 20:89-112, 2007 labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gy-

253. McDonald H, Brocklehurst P, Gordon A: Antibiotics for treating bac- necol 151:574-577, 1985

terial vaginosis in pregnancy. Cochrane Database Syst Rev 231. Goldstein P, Berrier J, Rosen S, et al: A meta-analysis of randomized

CD000262, 2007

control trials of progestational agents in pregnancy. Br J Obstet Gynae- 254. Carey JC, Klebanoff MA, Hauth JC, et al: Metronidazole to prevent col 96:265-274, 1989

preterm delivery in pregnant women with asymptomatic bacterial 232. Daya S: Efficacy of progesterone support for pregnancy in women

vaginosis. National Institute of Child Health and Human Develop- with recurrent miscarriage. A meta-analysis of controlled trials. Br J

ment Network of Maternal-Fetal Medicine Units. N Engl J Med 342: Obstet Gynaecol 96:275-280, 1989

534-540, 2000

233. Keirse MJ: Progestogen administration in pregnancy may prevent pre- 255. Carey JC, Klebanoff MA: What have we learned about vaginal infec- term delivery. Br J Obstet Gynaecol 97:149-154, 1990

tions and preterm birth? Semin Perinatol 27:212-216, 2003 234. Meis PJ, Aleman A: Progesterone treatment to prevent preterm birth.

256. Riggs MA, Klebanoff MA: Treatment of vaginal infections to prevent Drugs 64:2463-2474, 2004

preterm birth: a meta-analysis. Clin Obstet Gynecol 47:796-807, 235. Noblot G, Audra P, Dargent D, et al: The use of micronized proges-

terone in the treatment of menace of preterm delivery. Eur J Obstet 257. Odendaal HJ, Popov I, Schoeman J, et al: Preterm labour: is bacterial Gynecol Reprod Biol 40:203-209, 1991

vaginosis involved? S Afr Med J 92:231-234, 2002 236. Iams JD: Supplemental progesterone to prevent preterm birth. Am J

258. Kekki M, Kurki T, Pelkonen J, et al: Vaginal clindamycin in preventing Obstet Gynecol 188:303, 2003

preterm birth and peripartal infections in asymptomatic women with